Northland Securities set a $25.00 target price on NxStage Medical Inc. (NASDAQ:NXTM) in a research report report published on Thursday morning. The firm currently has a a buy rating on the medical device company’s stock.

Several other equities research analysts have also recently commented on the stock. Zacks Investment Research cut shares of NxStage Medical from a buy rating to a hold rating in a research report on Wednesday, August 10th. BTIG Research reiterated a buy rating and issued a $29.00 price target on shares of NxStage Medical in a research note on Sunday, August 7th. Jefferies Group increased their price target on shares of NxStage Medical from $24.00 to $27.00 and gave the stock a buy rating in a research note on Friday, August 5th. Canaccord Genuity increased their price target on shares of NxStage Medical from $22.00 to $26.00 and gave the stock a buy rating in a research note on Tuesday, August 2nd. Finally, Piper Jaffray Cos. reiterated a buy rating and issued a $21.00 price target on shares of NxStage Medical in a research note on Friday, June 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. NxStage Medical currently has a consensus rating of Buy and an average target price of $26.43.

NxStage Medical (NASDAQ:NXTM) opened at 24.21 on Thursday. The stock’s market capitalization is $1.56 billion. The firm has a 50-day moving average of $23.69 and a 200-day moving average of $19.60. NxStage Medical has a 1-year low of $13.49 and a 1-year high of $26.07.

NxStage Medical (NASDAQ:NXTM) last posted its earnings results on Thursday, August 4th. The medical device company reported ($0.03) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.01. NxStage Medical had a negative net margin of 2.06% and a negative return on equity of 3.79%. The firm earned $92.20 million during the quarter, compared to analysts’ expectations of $89.44 million. During the same period last year, the company posted ($0.08) EPS. The company’s quarterly revenue was up 14.8% compared to the same quarter last year. Equities analysts expect that NxStage Medical will post ($0.12) EPS for the current fiscal year.

In other NxStage Medical news, Director Craig W. Moore sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $23.31, for a total transaction of $69,930.00. Following the completion of the sale, the director now directly owns 90,739 shares in the company, valued at approximately $2,115,126.09. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 4.70% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. HBK Investments L P raised its stake in NxStage Medical by 86.6% in the first quarter. HBK Investments L P now owns 63,100 shares of the medical device company’s stock worth $946,000 after buying an additional 29,291 shares in the last quarter. Deerfield Management Co. increased its stake in shares of NxStage Medical by 20.0% in the first quarter. Deerfield Management Co. now owns 5,506,028 shares of the medical device company’s stock worth $82,535,000 after buying an additional 917,028 shares during the last quarter. Nuveen Asset Management LLC increased its stake in shares of NxStage Medical by 11.2% in the first quarter. Nuveen Asset Management LLC now owns 336,055 shares of the medical device company’s stock worth $5,037,000 after buying an additional 33,974 shares during the last quarter. Menta Capital LLC bought a new stake in shares of NxStage Medical during the first quarter worth about $552,000. Finally, GSA Capital Partners LLP increased its stake in shares of NxStage Medical by 98.4% in the second quarter. GSA Capital Partners LLP now owns 40,426 shares of the medical device company’s stock worth $876,000 after buying an additional 20,046 shares during the last quarter. Institutional investors and hedge funds own 98.26% of the company’s stock.

About NxStage Medical

NxStage Medical, Inc is a medical device company. The Company is engaged in the development, manufacturing and marketing of products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s products include the System One, Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles.

5 Day Chart for NASDAQ:NXTM

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.